(MedPage Today) — FDA warns that Cipro and similar antibiotics should not be used for uncomplicated infections
Category: News
Vehicle side windows offer low protection from UVA rays, study finds
A researcher finds that the side windows of automobiles offer low protection from UVA radiation, which he says could be a key contributor to skin cancer and cataracts.
How to Avoid Misdiagnosis
(MedPage Today) — How a patient makes you feel may affect your diagnostic acumen
Crosslinking-Enhanced LASIK Does Not Add Benefit at 6 Months
The addition of corneal crosslinking, recently approved by the FDA, to LASIK surgery does not significantly preserve visual acuity, a prospective study shows. Medscape Medical News
Crosslinking-Enhanced Hyperopic LASIK: No Regression Benefit
The addition of corneal crosslinking, recently approved by the FDA, to LASIK surgery does not significantly preserve visual acuity, a prospective study shows. Medscape Medical News
Repetitive, subconcussive head impacts from football associated with short-term changes in eye function
In a study that included 29 NCAA football players, repetitive subconcussive impacts were associated with changes in near point of convergence (NPC) ocular-motor function among players in the…
Federal Judge Rules Against ACA Subsidies
(MedPage Today) — But gives Obama administration time to appeal
Global Proliferative Diabetic Retinopathy (PDR) Pipeline Report 2016 – Review 7 Companies & Drug Profiles – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Proliferative Diabetic Retinopathy (PDR) – Pipeline Review, H1 2016” report to their offering. This report provides comprehensive information on the therapeutic developmen…
Ocular Hypertension Following Intravitreal Anti-VEGF Therapy
Ocular hypertension can be a potential side effect of treatment with anti-VEGF agents. What role does intraocular nitric oxide have in the development of this complication? Journal of Glaucoma
Global Bacterial Conjunctivitis Pipeline Review, H1 2016 – Analysis, Technologies & Forecasts Report – Key Vendors: Cellceutix, InSite Vision, Shire – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Bacterial Conjunctivitis – Pipeline Review, H1 2016” report to their offering. The report provides comprehensive information on the therapeutics under development for Bact…
Extended-Range Intraocular Lens Improves Visual Acuity
An extended-range-of-vision intraocular lens improves visual acuity better than a monofocal intraocular lens, and is just as safe, new research shows. Medscape Medical News
Inotek Pharmaceuticals Corporation Reports First Quarter 2016 Financial Results and Operational Highlights
LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek today reported financial results and operational highlights for the quarter ended March 31, 2016.
Long-term survival achieved in metastatic melanoma with personalized vaccine
Two patients with melanoma that had spread to the liver survived for at least 8.5 and 12 years after resection of the hepatic tumor and treatment with patient-specific immunotherapeutic vaccines.
Women Aren’t Taking First Place in Top Medical Journals
(MedPage Today) — Unconscious bias may be an issue
Persistent Diabetic Macular Edema: Converting Eyes to Aflibercept
In patients with persistent diabetic macular edema, switching from an older VEGF inhibitor to a newer one may improve outcomes. Conversion to aflibercept may now be another option. Medscape Medical News
Omeros Corporation Reports First Quarter 2016 Financial Results
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting infl…
Leonard M. Blum Joins Omeros to Lead Business and Commercial Activities
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced the hiring of Leonard Blum as chief business and commercial officer. Mr. Blum is leading the company’s sales, marketing, commercial strategy and planning, and bu
Omeros Corporation Announces Exclusive Middle East Distribution Agreement for OMIDRIA®
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting infl…
Ocular Therapeutix™ Reports First Quarter 2016 Financial Results and Provides Corporate Update
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the first quarter ended March 31, 2016. “This is an exciting time for Ocular Therapeutix, as we anticipate multiple key milestones throughout the remainder of 2016, including the July 2016 PDUFA date for DEXTENZA for the treatment of post-surgical
Intraocular therapy prevents or reverses diabetic retinopathy in mice
Agent leads to overexpression of angiotensin converting enzyme-2, according to a new report in The American Journal of Pathology.